← Back to Search

Virus Therapy

GL-ONC1 alone, or in combination with chemotherapy with or without bevacizumab for Ovarian Cancer

Phase 1 & 2
Waitlist Available
Research Sponsored by Genelux Corporation
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up by medical chart review until death or 3 years from the date of last treatment which ever comes first.
Awards & highlights

Study Summary

This trial is testing a new cancer treatment to see if it is effective and has few side effects.

Eligible Conditions
  • Ovarian Cancer
  • Peritoneal Carcinomatosis

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~by medical chart review until death or 3 years from the date of last treatment which ever comes first.
This trial's timeline: 3 weeks for screening, Varies for treatment, and by medical chart review until death or 3 years from the date of last treatment which ever comes first. for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Determine Progression-free Survival following Treatment (Phase 2)
Incidence of Treatment-emergent Adverse Events [Safety and Tolerability] (Phase 1b)
Overall Response Rate (ORR) by RECIST 1.1 (Phase 2)
+1 more
Secondary outcome measures
CA-125 Response (Phase 1b)
Clinical Benefit Rate
Determine Progression-free Survival following Treatment (Phase 1b)
+3 more

Trial Design

1Treatment groups
Experimental Treatment
Group I: GL-ONC1Experimental Treatment1 Intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
GL-ONC1 alone, or in combination with chemotherapy with or without bevacizumab
2016
Completed Phase 2
~50

Find a Location

Who is running the clinical trial?

Genelux CorporationLead Sponsor
6 Previous Clinical Trials
271 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
GL-ONC1 Oncolytic Immunotherapy in Patients With Recurrent or Refractory Ovarian Cancer
2016. "GL-ONC1 Oncolytic Immunotherapy in Patients With Recurrent or Refractory Ovarian Cancer". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT02759588.
~5 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top